Alkermes is positioned for outperformance due to its conservative cash-heavy balance sheet and high-margin business model.

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise ...

"Each year, the spring scientific meetings bring together critical stakeholders from across the field of psychiatry to share insights and advance patient care; Alkermes is honored to have our research ...

? Results from Long-Term Safety Study and Data from Healthcare Resource Utilization Research Offer Insights into Treatment Experiences for People Living with Schizophrenia or Bipolar I Disorder ...

Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

A new study tested a well-known smoking cessation drug to see if it would work to help people to quit e-cigarettes.

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Fractyl Health, Inc. (GUTS – Research Report) today. The ...

In a report released on May 10, Paul Matteis from Stifel Nicolaus maintained a Hold rating on Denali Therapeutics (DNLI – Research ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Union Pacific Corporation (UNP), ...

The price-to-earnings ratio for Alkermes plc (NASDAQ:ALKS) is 9.65. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E ...